![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Grants QIDP and Fast Track Designations to RedHill’s Mycobacteria Antibiotic
FDA Grants QIDP and Fast Track Designations to RedHill’s Mycobacteria Antibiotic
January 20, 2017
FDA granted a Qualified Infectious Disease Product designation to RHB-104, an oral antibiotic developed by RedHill Biopharma for the treatment of nontuberculous mycobacteria infections.
The QIDP designation allows for fast-track status and priority review, and an additional five years of marketing exclusivity if approved. The infection’s course of treatment is typically prolonged and requires multi-drug regimens due to the risk of development of resistance.
RedHill is also evaluating RHB-104 in a Phase III trial for the treatment of Crohn’s disease, as well as a Phase IIa study examining the drug as an add-on therapy to interferon beta-1a in patients with relapsing remitting multiple sclerosis.
Upcoming Events
-
21Oct